Search Medical Condition
Please enter condition
Please choose location

Limerick, Ireland Clinical Trials

A listing of Limerick, Ireland clinical trials actively recruiting patients volunteers.

RESULTS

Found (25) clinical trials

An Investigational Immuno-therapy Trial of Nivolumab or Nivolumab Plus Ipilimumab or Nivolumab Plus Platinum-doublet Chemotherapy Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to show that Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum-Doublet Chemotherapy improves progression free survival and/or overall survival compared with chemotherapy in patients with advanced lung cancer.

Phase

0.0 miles

Learn More »

Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy

The investigational medicinal product denosumab is a protein (monoclonal antibody) that works to slow down bone destruction caused by cancer spreading to the bone (bone metastasis). Denosumab is used in adults with cancer to prevent serious complications caused by bone metastasis (e.g. fracture, pressure on the spinal cord or the ...

Phase

0.0 miles

Learn More »

Prospective Single-arm Multi Centre Observations Ultimaster Des Registry

All consecutive patients suitable for treatment with DES according to hospital routine practice in centres across the world that agree to participate in the e-ULTIMASTER registry will be treated with Ultimaster DES. Secondary objectives Evaluation of worldwide utilization of DES, Detection of rare events in representative patient population, identification of ...

Phase N/A

0.0 miles

Learn More »

Comparison of Efficacy and Tolerability of Fulvestrant+Placebo vs Fulvestrant+Palbociclib as First Line Therapy for Postmenopausal Women With HR+ Metastatic BC Treated With 5 Years of Hormonal Therapy Remaining Disease Free More Than 12 Months After Completion or Have de Novo Metastatic Disease

This is an international, multicentre, double-blind, controlled, randomized phase II study comparing the efficacy and safety of fulvestrant in combination with palbociclib versus fulvestrant plus placebo in postmenopausal women with HR-positive/HER2-negative metastatic breast cancer who have received 5 years of endocrine therapy in the adjuvant setting as treatment for early ...

Phase

0.0 miles

Learn More »

Study Of Diabetic Nephropathy With Atrasentan

The study objective is to evaluate the effect of atrasentan compared with placebo on time to doubling of serum creatinine or the onset of end stage renal disease (ESRD) in subjects with type 2 diabetes and nephropathy who are treated with the maximum tolerated labeled daily dose (MTLDD) of a ...

Phase

0.0 miles

Learn More »

Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma

The purpose of this study is to evaluate the efficacy and safety of pembrolizumab + epacadostat vs pembrolizumab + placebo as a treatment for recurrent or progressive metastatic urothelial carcinoma in patients who have failed a first-line platinum-containing chemotherapy regimen for advanced/metastatic disease.

Phase

0.0 miles

Learn More »

Nutritional Supplement and Bone Health in Post-Menopausal Women

Study Design: A block randomised, cross-over design of 24h rates of bone turnover in healthy, post-menopausal women with osteopenia receiving either a milk-based protein supplement (MBPS) or isoenergetic placebo control (PLACEBO). Participants: 16 Post-menopausal women with osteopenia as determined by site-specific bone mineral density BMD (DXA) diagnosed and screened by ...

Phase N/A

0.0 miles

Learn More »

Protein Supplementation and Recovery of Muscle Function

Study Design: A block randomised design of 3 groups of resistance-exercise trained (RET) men Participants: 24 young, healthy, resistance exercise trained, males aged 18 - 35 years. Recovery drinks; CONTROL - an isonitrogenous, non-essential amino acid solution; PROTEIN - a milk-based whey protein concentrate (WPC), WPC-80; HYDROLYSATE - a hydrolysed ...

Phase N/A

0.0 miles

Learn More »

Plasma Biomarkers P-DAC V1

This study will involve two cohort groups, all patients involved will have PDAC. Cohort A: Target is 80 resectable PDAC patients who will receive standard treatment of chemotherapy +/- radiotherapy Cohort B: Cohort B1 = Target is 80 unresectable locally advanced PDAC patients who will receive standard treatment of chemotherapy ...

Phase N/A

0.0 miles

Learn More »

Plasma Biomarkers C-RAC ICORG 12-27 V1

Cohort A will consist of 100 CRAC patients with stage II/III resectable disease due for adjuvant chemotherapy. Cohort B will consist of 30 patients with stage II resectable disease for observation only. Both cohorts will have a follow up period of up to 2 years, post chemotherapy for cohort A ...

Phase N/A

0.0 miles

Learn More »